Novo Nordisk's FREHEMGO® Recommended for EU Approval, Expanding Haemophilia A Treatment Options
Event summary
- CHMP recommends EU approval of FREHEMGO® (denecimig) for haemophilia A treatment in adults and children.
- FREHEMGO® offers flexible dosing options (monthly, bi-weekly, weekly) via a pre-filled pen.
- Novo Nordisk plans EU launch in Q4 2026, with broader rollout in early 2027.
- FRONTIER trial programme demonstrated significant reduction in annualised bleeding rates.
- Denecimig showed preference over emicizumab in device usability studies.
The big picture
Novo Nordisk's FREHEMGO® represents a strategic advancement in haemophilia A treatment, offering a differentiated product with flexible dosing and a user-friendly delivery system. This approval positions Novo Nordisk to compete more aggressively in the haemophilia market, particularly against Roche's emicizumab. The success of FREHEMGO® could influence the broader landscape of rare disease treatments, emphasizing the importance of convenience and patient-centric design in therapeutic innovation.
What we're watching
- Regulatory Momentum
- Whether the FDA approval process for denecimig will follow a similar timeline to the EU, given the September 2025 BLA submission.
- Market Penetration
- The pace at which Novo Nordisk can capture market share from existing haemophilia A treatments, particularly emicizumab.
- Clinical Adoption
- How healthcare providers and patients respond to the flexible dosing options and pre-filled pen delivery system.